Funding for this research was provided by:
Foundation for the National Institutes of Health (A1128194)
Swiss Government Excellence schorlaship (2016.056)
Equatorial Guinea Malaria Vaccine Initiative
Received: 24 August 2020
Accepted: 20 January 2021
First Online: 26 January 2021
Ethics approval and consent to participate
: The studies were registered at Clinicaltrial.gov. under the registration numbers NCT02132299 (BSPZV1), NCT02613520 (BSPZV2), NCT03420053 (BSPZV3a) and NCT02859350 (EGSPZV2). All clinical trials were approved by the Institutional Review Board for the Ifakara Health Institute (IHI-IRB), Tanzanian Food and Drug Administration (TFDA), Tanzanian National Institute for Medical Research (NIMR) and the Ethical Committee of Northern and Central Switzerland (EKNZ). Written informed consent was obtained from all participants prior enrolment. All trial procedures were conducted in accordance to good clinical practice (GCP) and under the Declaration of Helsinki.
: Not applicable.
: The authors declare that they have no competing interests.